TL;DR
AI governance in healthcare decides which AI tools a provider, payer or life sciences team may use, under what checks, and who answers for them. Start by ranking each use by how much harm a wrong output could do to a patient. A scribe drafting notes needs lighter review than a model that shapes diagnosis or coverage. Then map each tool to the rules that apply, such as HIPAA, FDA device rules, the Section 1557 bias duty and state disclosure laws. A cross-functional committee approves the high-risk uses and keeps the evidence. After go-live, monitor every model locally and send it back for review when the vendor changes it.
Key Takeaways Govern each AI workflow by the patient harm a wrong output could cause, not by the vendor or product name. HIPAA covers the data, but FDA rules, the Section 1557 bias duty and state laws cover the decisions. The HTI-5 rule drops EHR model-card duties, so health systems must now ask vendors for that information. A governance committee needs clinical, privacy, compliance, security, legal and patient safety voices with clear approval rights. Local validation and subgroup testing before go-live matter more than a vendor’s headline accuracy figure. Model updates, new data sources and new patient groups should all trigger a fresh review. Watch on YouTube
Can AI Transform Healthcare: Trends and Technologies to Watch
Kanerika looks at where AI is already changing care delivery and operations, the same spread of tools a healthcare governance program must cover.
The 2 A.M. Sepsis Alert
At 2 a.m. on a medical ward, a sepsis alert flashes on the charge nurse’s screen. Because she has seen that alert many times this week, mostly on patients who turned out fine, she barely pauses. She checks the vitals, clears it and moves on. Meanwhile, a patient two beds down gets sicker without ever triggering it.
That scene mirrors a 2021 JAMA Internal Medicine study in which Michigan Medicine researchers tested the Epic Sepsis Model on 38,455 hospitalizations. The model missed 67% of the patients who developed sepsis , yet it alerted on 18% of everyone admitted. It was already running at hundreds of US hospitals before that independent check appeared.
Nobody in that story set out to cut corners. Still, no one had clearly owned the question of whether the model worked on local patients. Closing that ownership gap is the whole job.
What AI Governance in Healthcare Has to Control
AI governance in healthcare is the set of decisions, owners and evidence behind every AI tool a health organization runs. In short, it answers three questions. Which tools may we use, what checks must each one pass, and who is accountable when one gets it wrong?
Three things make the healthcare version harder than the general enterprise AI governance playbook. First, a wrong output can reach a patient’s body, not just a spreadsheet. Second, prompts, recordings and logs are full of protected health information. Third, the clinician who signs the note stays accountable, even when a model wrote the draft.
Bias adds a fourth layer, often hidden in reasonable design choices: a care-management algorithm studied in Science in 2019 predicted health costs instead of illness . Black patients therefore had to be sicker to get the same risk score. Fixing that proxy would have raised the share of Black patients flagged for extra help from 17.7% to 46.5%.
This is also where AI governance stops and data governance begins, a split our guide to data governance in healthcare covers. AI governance sits on top, because a model is only as trustworthy as the records it learns from.
Which Healthcare AI Needs Which Level of Review?
Healthcare organizations now run a wide mix of AI, from ambient scribes to AI agents for healthcare that book visits or update records. Giving all of them the same review either stalls the safe tools or waves through the risky ones. A tiered model fixes that by matching the depth of review to the stakes.
Factors That Set the Tier
Five questions decide most tiers. Does the output touch patient care or only operations? How much PHI does the tool see? Can a human review the output before it acts? Can the action be undone, and how many people does the tool reach?
Reversibility and reach matter most. A drafted email can be deleted, but an EHR order or a denied claim hits a real person at once. Similarly, a tool used by ten coders carries less exposure than one used across every clinic.
A Working Tier Table
The table below is an internal scheme, not a legal classification, so adjust the tiers to your own workflows and risk appetite.
Table 1: Healthcare AI use cases mapped to review tier, owner, evidence and human checkpoint
AI use case Tier Primary reviewer Evidence before go-live Human checkpoint Internal assistant on non-PHI data 1 (low) IT and process owner Acceptable-use check, data-source approval Spot checks Coding and revenue cycle support 2 (moderate) Revenue cycle lead and compliance Coding accuracy sample, denial-impact test Coder approves each code Ambient AI scribe 2 (moderate) CMIO and clinical lead Accuracy and omission testing, privacy review Clinician signs the final note Patient-facing chatbot 3 (high) Patient safety and privacy leads Unsafe-advice scenarios, escalation tests, disclosure check Hand-off to a human on clinical questions Clinical risk prediction or diagnostic AI 3 (high) Clinical safety committee and regulatory lead FDA status, local validation, subgroup results Clinician reviews every recommendation Agent that writes to the EHR or decides coverage 3 (high) CMIO, IT security and patient safety Permission tests, action logs, rollback test Approval before each consequential action
Above all, classify the workflow, not the product name. An ambient scribe that only drafts notes sits at tier 2, but the same tool moves to tier 3 once it starts placing orders. Agents also need the controls covered in our guide to agentic AI governance .
Checklist
AI Governance Checklist
A step-by-step checklist for inventorying AI tools, assigning owners and setting review rules, so your committee starts with a working agenda.
Get the Checklist → Shadow Generative AI Belongs in the Inventory
Generative tools that staff adopt on their own belong in the inventory too. For instance, a clinician pasting a discharge summary into a public chatbot creates PHI exposure with no review at all. Our guides to generative AI governance and shadow AI cover how to find and control that usage.
The Rules Behind AI Governance in Healthcare in 2026
No single US law governs healthcare AI. Instead, several rules each cover one slice, and the slices shift quickly. Here is how they fit together for US organizations as of November 2026.
HIPAA and PHI in Prompts
HIPAA does not mention AI, but it applies the moment a tool touches protected health information. The minimum necessary standard limits how much PHI a prompt, upload or training set may carry. The same section requires satisfactory assurance, usually a business associate agreement, before PHI goes to a vendor. Logs and recordings count too, because they often hold more PHI than the final note.
Watch on YouTube
Microsoft Fabric for Healthcare: HIPAA Setup Guide (2026)
A practical walkthrough of setting up a HIPAA-ready data platform, so the PHI your AI tools read is classified, access-controlled and logged.
FDA Rules for AI Devices and Clinical Decision Support
Some clinical AI is a regulated medical device. The FDA keeps a public list of AI-enabled medical devices authorized for the US market. By our count of that list, it holds more than 1,600 entries, and roughly three in four sit in radiology.
Other tools, however, fall outside the device definition. The FDA’s clinical decision support guidance , finalized in January 2026, explains which decision support software counts as non-device. Even so, a tool outside FDA oversight still needs local governance, because nobody else will check it for you.
The Section 1557 Bias Duty
Federal civil rights rules now reach clinical algorithms directly. Under 45 CFR 92.210 , covered entities must make reasonable efforts to find decision support tools with sensitive inputs. Specifically, those inputs are race, color, national origin, sex, age or disability. They must then reduce the risk of discrimination those tools create.
That duty has applied since May 1, 2025, and it turns bias testing from a nice-to-have into a documented, recurring control.
ONC Decision Support Rules After HTI-5
The HTI-1 rule had required certified EHR developers to expose “source attributes” for predictive decision support, a kind of model card. ONC’s HTI-5 final rule , published October 28, 2026, removes those source attribute and risk management requirements. It takes effect December 28, 2026.
For a health system, the practical effect is a shift in who asks. So model details that once arrived through EHR certification must now be requested in the vendor contract.
State Disclosure Laws
States are adding their own patient-facing rules. Since January 1, 2025, California’s AB 3030 requires facilities, clinics and physician offices to tell patients when generative AI wrote a clinical message. The exception applies when a licensed provider reads and reviews the message first.
Multistate systems and payers should track these laws in one register, so a chatbot launched in one state does not break another state’s rules. This also matters for the virtual care teams covered in our post on AI in telemedicine .
EU AI Act and Voluntary Frameworks
Medical device makers and life sciences firms selling in Europe face the EU AI Act. After the Digital Omnibus amendments, rules for high-risk AI in regulated products such as medical devices apply from August 2, 2028. Our EU AI Act compliance guide covers provider and deployer duties.
Voluntary frameworks fill the gaps. For instance, the NIST AI Risk Management Framework gives a shared risk vocabulary (our NIST AI RMF playbook turns it into actions). Similarly, the WHO guidance on AI for health sets six ethical principles. Joint Commission and CHAI also released responsible AI guidance in September 2025, with a voluntary certification planned.
The Rules Side by Side
Table 2: The healthcare AI rules that apply in 2026 and what each one asks for
Rule Applies to What it asks for Status in November 2026 HIPAA Privacy and Security Rules Covered entities and business associates handling PHI Minimum necessary PHI, business associate agreements, safeguards In force FDA device rules and CDS guidance AI that meets the medical device definition Authorization, intended use, change control CDS guidance final, January 2026 Section 1557, 45 CFR 92.210 Covered health programs using decision support tools Identify and reduce discrimination risk In force since May 1, 2025 ONC HTI-5 Certified health IT developers Removes DSI source attribute and risk management duties Effective December 28, 2026 California AB 3030 California facilities, clinics and physician offices Disclose generative AI in clinical messages In force since January 1, 2025 EU AI Act, Annex I AI in regulated products sold in the EU, including medical devices High-risk obligations for providers and deployers Applies from August 2, 2028
Regulatory scope and internal tier are different labels, so a tool outside FDA oversight can still sit at tier 3. For a wider view of how these duties connect, see our overview of AI compliance .
Kanerika Service
AI Governance Consulting Services
Kanerika designs tier rules, committee roles and controls that keep clinical and operational AI auditable and inside your risk limits.
Explore AI Governance Services Who Sits on the Healthcare AI Governance Committee?
Rules only work when someone owns them. Most health systems need one cross-functional AI governance committee that reports to the executive team and approves the high-tier uses.
The Seats That Matter
CMIO or chief clinical officer. Owns clinical safety and the final call on clinical use.Chief privacy officer. Owns PHI use, business associate agreements and patient disclosures.Chief compliance officer and legal. Track federal and state rules and review vendor contracts.CISO. Owns access, logging and security testing.Patient safety or quality lead. Reviews incidents and harm reports.Clinical informatics and data science. Run validation and monitoring.Payers should also add revenue cycle and medical management leaders, and life sciences firms should add regulatory affairs. Also give a seat to a frontline nurse or physician, because they see failure modes that committees miss.
What the Committee Decides
The committee should own four decisions. It approves tier assignments, signs off tier 3 deployments, sets the evidence each tier needs and decides when a model must pause. Tier 1 tools can be approved by a delegate in days, so the committee spends its time on the risky cases.
After each meeting, every decision gets a short written record. It lists the use case, tier, owner, evidence reviewed, conditions and next review date. Over time, those records become your audit trail, and they line up well with the governance functions in our AI governance framework guide.
An AI Use Policy and Training for Clinicians and Staff
The committee governs the tools it knows about, while an acceptable-use policy covers the rest. Clinicians are also moving fast: an AMA survey found 66% of physicians used health AI in 2024, up from 38% in 2023. A one-page policy should state five things.
Which tools are approved, and how to request a new one. What may never go into an unapproved tool, starting with PHI, because public chatbots sit outside any business associate agreement. That the clinician who signs a note or order owns its content, whoever drafted it. When patients must be told AI was involved, as AB 3030 requires for some messages. How to report an AI error or near miss. Training is not optional either, because two existing duties already require it. The HIPAA training standard requires every workforce member to be trained on PHI policies, so add AI prompts, uploads and recordings to that module. The Section 1557 training rule covers staff whose decisions affect patient care, which makes it the place to teach the bias duty.
Then make the training role-based. Clinicians learn to spot a wrong draft, coders learn the escalation path, and committee members learn to read a validation report.
Validation, Bias Testing and Monitoring
A vendor’s accuracy figure describes the vendor’s test data, not your patients. A 2024 follow-up in NEJM AI, covering 77,582 hospitalizations, showed how wide that gap can get. Counting only predictions made before clinicians had started treatment, the Epic model’s AUROC fell to 0.47 , no better than chance.
The evidence pack for any tier 3 tool should therefore be built on local data.
The Evidence Pack Before Go-Live
An intended-use statement and a map of the clinical workflow it changes. Model version, training data summary and known limits, supplied by the vendor. Local validation results on a recent, representative patient sample. Performance split by age, sex, race, ethnicity, language and payer type. The human review step, escalation path and named clinical owner. A monitoring plan with the thresholds that trigger a pause. Subgroup results are also where the Section 1557 duty becomes concrete. Our guide to explainable AI covers ways to show clinicians why a model flagged a patient, and our responsible AI guide covers the wider ethics.
What to Watch After Launch
Models drift because patient mix, coding rules and clinical practice change. Track accuracy against outcomes, alert rates, override rates and subgroup gaps. In fact, a rising override rate is often the first sign clinicians have stopped trusting the output.
Write the pause rule before launch so nobody has to argue about it at 2 a.m. The values below are illustrative starting points, not regulatory requirements, so calibrate them to your own baseline and patient volume.
Drift: sensitivity more than 5 points below the local baseline over a rolling 30 days pauses the tool.Subgroup gap: any group trailing the overall figure by more than 5 points opens a bias review within 10 business days.Trust: an override rate that doubles against the first month triggers a clinical review.Cadence: review tier 3 monthly, tier 2 quarterly and tier 1 yearly.Authority: the clinical owner or patient safety lead can pause alone, but only the committee can restart.For example, say a deterioration model validated at 80% sensitivity overall scores 72% for patients whose preferred language is not English. That 8-point gap breaches the example trigger, so the record must show what changed or why use continues.
AI observability tools and MLOps consulting can wire those thresholds into the deployment pipeline, and predictive models need it most.
Vendor Contracts and Model Change Control
Most healthcare AI is bought rather than built. That makes the contract the main governance tool, especially after HTI-5.
Questions to Ask Before You Buy
What data trained the model, and how closely does it match our patient population? What is the FDA status, and what intended use does it cover? Will our PHI, prompts or outputs train the vendor’s models? Who are the subcontractors, and do they sit under the business associate agreement? How will we hear about model updates, and how far in advance? For generative and agent tools, also add questions on prompt injection, output filtering and access scope. Our LLM security guide and our post on AI guardrails list the controls worth asking about.
Changes That Should Trigger a New Review
A model that passed review last year is not the model running today, because vendors retrain and swap foundation models in routine updates. Each of these changes should send the tool back to its reviewer.
New model versions, or a swap of the underlying foundation model. New data sources, or use on a patient group it was not validated on. Wider scope, such as moving from drafting to acting. Any monitoring threshold breach or reported incident. FDA-cleared devices can carry a predetermined change control plan that pre-approves certain updates. That plan covers the maker’s regulatory duty, not yours, so ask for it then decide which of its changes still need local revalidation. Our post on AI agent lifecycle management describes the same discipline for agents.
When a Healthcare AI Model Causes Harm
Sooner or later, a model will give a wrong answer that reaches a patient or leaks data. So treat that as a patient safety event first and a technology problem second.
An AI incident can be a harmful recommendation, a missed alert, a biased pattern or PHI exposed through a prompt or log. It can also be an agent taking an action it was never meant to take, a risk our post on rogue AI walks through. The response then runs from triage and containment to patient impact review, root-cause analysis, corrective action and reapproval before the tool returns.
Some incidents also carry outside reporting duties, so speed matters. If PHI was breached, HIPAA requires notice to affected people without unreasonable delay and within 60 calendar days of discovery. Device problems may also need reports to the FDA and the maker, so legal should join the triage call early.
A 90-Day Start for Providers, Payers and Life Sciences
A healthcare AI governance program does not need a year of design before it helps. Instead, ninety days is enough to cover the tools that carry the most risk.
First 30 days: inventory every AI tool, including EHR features and tools staff adopted on their own. Give each a provisional tier and an owner. Days 31 to 60: charter the committee, publish the tier rules, evidence packs and AI use policy, and start staff training. Review every live tier 3 tool, starting with diagnosis, treatment and coverage. Days 61 to 90: validate the top tier 3 tools on local data and switch on monthly monitoring. Run an incident tabletop exercise and report gaps to the board. Our AI governance assessment guide shows how to score where you stand.
AI Assessment
Where Does Your Healthcare AI Program Stand?
Score your AI foundations, generative AI and agent readiness in a few minutes and see which governance steps to take first.
Start Your AI Assessment → Payers should put prior authorization and claims models at the front of the queue, because a wrong denial lands on a member right away. Similarly, life sciences teams should start with AI used in trial screening, safety monitoring and regulated product work, where FDA and EU duties apply.
How Kanerika Helps Healthcare Teams Govern AI
Kanerika’s AI governance services follow our IMPACT framework (Identify, Map, Prove, Analyze, Create, Transform). In practice that means model impact assessments before deployment, bias testing after launch and a model registry with a full audit trail. Each of those also maps to the tiers, evidence packs and pause rules above.
In our healthcare work, AI review often stalls on a data question first. Which PHI does this tool touch, and who may see it?
For a top North American healthcare organization, Kanerika built a Purview-based centralized data catalog and classification framework with steward roles and usage policies. Data discovery time then fell by 57% and compliance adherence rose by 90%. That was data governance, not model review, yet labeled and owned PHI is what lets an AI inventory show which data each tool reads.
For a healthcare workforce platform, our AI document verification and onboarding reached 90% operational AI accuracy and cut wastage by 64%. Outside healthcare, an AI compliance agent we built for an expert network shows the Table 1 checkpoint in practice. It cites every finding and maps it to the client’s rulebook, so analysts review rather than research, and vetting runs 3x faster.
Our data governance services and data lineage work keep every model input traceable. Kanerika also holds ISO 27001, ISO 27701:2019 and SOC 2 Type II, which matters when a partner handles patient data. Read more on our AI in healthcare page.
Case Study
90% Compliance Adherence for Healthcare with Purview
A top North American healthcare organization used Microsoft Purview to cut data discovery time by 57% and raise compliance adherence by 90%.
Read the Case Study → Wrapping Up
AI governance in healthcare comes down to a few habits held in place by clear owners. Rank every AI workflow by the harm it could do, and map it to HIPAA, FDA, Section 1557 and state rules. Then demand local evidence before go-live, train the people who use it and keep watching after launch. Done well, the next 2 a.m. alert is one a nurse can trust, because someone checked it on her patients first.
Frequently Asked Questions
What is AI governance in healthcare?
AI governance in healthcare is the program of decisions, owners and evidence that controls which AI tools a provider, payer or life sciences company uses. It sets review depth by patient risk, maps each tool to HIPAA, FDA and civil rights rules, and names who is accountable when a model gets something wrong.
Why does AI governance matter for hospitals?
Hospital AI can affect diagnosis, treatment and patient data, so a wrong output can harm a real person. Governance makes sure each tool is tested on local patients, watched after launch and paused when it drifts. It also gives the hospital an audit trail when regulators, accreditors or patients ask how a decision was made.
Who is responsible for AI governance in a hospital?
Most hospitals use a cross-functional AI governance committee that reports to the executive team. It usually includes the CMIO, the chief privacy officer, compliance and legal, the CISO, a patient safety lead and clinical informatics. Each AI tool also gets a named clinical or business owner who answers for its day-to-day performance.
Is HIPAA compliance enough for healthcare AI governance?
No. HIPAA protects patient data, but it says little about whether a model is accurate, fair or safe to act on. Health organizations also need FDA checks for device software, the Section 1557 bias duty for decision support tools, state disclosure laws and local validation and monitoring of every high-risk model.
Does every healthcare AI tool need FDA approval?
No. Only AI that meets the medical device definition needs FDA authorization. The FDA’s January 2026 clinical decision support guidance explains which decision support software falls outside that definition. Tools outside FDA oversight, such as many scribes and revenue cycle models, still need internal review because no regulator checks them for you.
What does the HTI-5 rule change for healthcare AI?
HTI-5, published October 28, 2026 and effective December 28, 2026, removes the HTI-1 requirements for certified EHR developers to expose source attributes and risk management details for predictive decision support. Health systems that want that model information now need to request it through procurement and vendor contracts instead of relying on certification.
How should healthcare organizations test AI for bias?
Test performance on a recent local patient sample and split the results by age, sex, race, ethnicity, language and payer type. Look for groups where accuracy drops or alerts behave differently. Record what was changed or why use continues, since Section 1557 requires reasonable efforts to identify and reduce discrimination risk.
How often should healthcare AI systems be reviewed?
High-risk clinical models should be monitored monthly for accuracy, alert rates, override rates and subgroup gaps, with a full review at least once a year. Any new model version, new data source, new patient group or wider scope should trigger a fresh review, as should a reported incident or a monitoring threshold breach.
What is the difference between responsible AI and AI governance in healthcare?
Responsible AI describes the principles, such as fairness, transparency, safety and accountability. AI governance is the operating program that puts those principles to work through tiers, committees, evidence requirements, contracts and monitoring. In healthcare, governance is what turns a principle like fairness into a documented bias test before a model goes live.
Which frameworks guide AI governance in healthcare?
Common references include the NIST AI Risk Management Framework, the WHO guidance on ethics and governance of AI for health, and the Joint Commission and CHAI guidance on responsible AI use. Organizations selling medical devices in Europe also need the EU AI Act, whose rules for high-risk AI in regulated products apply from August 2, 2028.
